Ofer Margalit, Sivan Lieberman, Ilanit Redinsky, Sharon Halparin, Nir Honig, Stephen Raskin, Maoz Ben-Ayun, Einat Shacham-Shmueli, Naama Halpern, Damien Urban, Aliza Ackerstein, Katerina Shulman, Eytan Ben-Ami, Valeriya Semenisty, Ofer Purim, Nirit Yarom, Talia Golan, Ben Boursi, Sarit Appel, Zvi Symon, Raanan Berger, David Mauro, Art M Krieg, Yaacov R Lawrence
INTRODUCTION: Microsatellite stable metastatic colorectal cancer (MSS mCRC) is largely refractory to immune checkpoint inhibition. We hypothesized that a combination of intratumoral TLR9 agonist, radiosurgery and dual PD-1 and CTLA-4 blockade would induce a local focus of immune stimulation, evoking a systemic immune response. PATIENTS AND METHODS: In this phase I single-institution study, patients with MSS mCRC were treated with a priming dose of s.c vidutolimod, 3 intratumoral injections of vidutolimod and radiosurgery, combined with nivolumab and ipilimumab...
August 9, 2023: Clinical Colorectal Cancer